When a second tumor arises in the contralateral breast in a patient with a previous or synchronous breast cancer, it is of clinical importance to determine if this tumor is a new unrelated tumor or a metastasis, i.e. clone, of the primary tumor. A new, unrelated tumor may be treated similarly as the first one since treatment was successful, while a distant metastasis demands a change of therapy and has a more adverse prognosis. In clinic, a second tumor is generally regarded as a new primary. If there is clinical suspicion that the second tumor may be a metastasis, clinico-pathological characteristics of the two tumors are used assess the clonality status. Clinico-pathological characteristics, however, are not reliable predictors to determi...
Multiple tumors in patients are frequently diagnosed, either synchronous or metachronous. The distin...
INTRODUCTION: Lobular carcinoma in situ (LCIS) has been accepted as a marker of risk for the develop...
Intra-tumor heterogeneity presents itself through the evolution of subclones during cancer progressi...
Abstract Background Molecular classification of tumour clonality is currently not evaluated in multi...
<div><p>Background</p><p>Synchronous tumors can be independent primary tumors or a primary-metastati...
Synchronous tumors can be independent primary tumors or a primary-metastatic (clonal) pair, which ma...
By convention, a contralateral breast cancer (CBC) is treated as a new primary tumor, independent of...
When a cancer patient develops a new tumor it is necessary to determine if this is a recurrence (met...
BACKGROUND: Breast cancer patients have a cumulative lifetime risk of 2%-15% of developing a contral...
<div><p>Cancers arise from successive rounds of mutation and selection, generating clonal population...
Cancers arise from successive rounds of mutation and selection, generating clonal populations that v...
A b s t r a c t We studied the clonality relationships in invasive breast carcinomas, ipsilateral br...
Female BRCA1/2 mutation carriers affected with breast and/or ovarian cancer may develop new tumor de...
BACKGROUND: Patients with breast cancer have an increased risk of developing subsequent breast cance...
The clonal origin of multiple tumors in the same individual has long been debated. The main aim of t...
Multiple tumors in patients are frequently diagnosed, either synchronous or metachronous. The distin...
INTRODUCTION: Lobular carcinoma in situ (LCIS) has been accepted as a marker of risk for the develop...
Intra-tumor heterogeneity presents itself through the evolution of subclones during cancer progressi...
Abstract Background Molecular classification of tumour clonality is currently not evaluated in multi...
<div><p>Background</p><p>Synchronous tumors can be independent primary tumors or a primary-metastati...
Synchronous tumors can be independent primary tumors or a primary-metastatic (clonal) pair, which ma...
By convention, a contralateral breast cancer (CBC) is treated as a new primary tumor, independent of...
When a cancer patient develops a new tumor it is necessary to determine if this is a recurrence (met...
BACKGROUND: Breast cancer patients have a cumulative lifetime risk of 2%-15% of developing a contral...
<div><p>Cancers arise from successive rounds of mutation and selection, generating clonal population...
Cancers arise from successive rounds of mutation and selection, generating clonal populations that v...
A b s t r a c t We studied the clonality relationships in invasive breast carcinomas, ipsilateral br...
Female BRCA1/2 mutation carriers affected with breast and/or ovarian cancer may develop new tumor de...
BACKGROUND: Patients with breast cancer have an increased risk of developing subsequent breast cance...
The clonal origin of multiple tumors in the same individual has long been debated. The main aim of t...
Multiple tumors in patients are frequently diagnosed, either synchronous or metachronous. The distin...
INTRODUCTION: Lobular carcinoma in situ (LCIS) has been accepted as a marker of risk for the develop...
Intra-tumor heterogeneity presents itself through the evolution of subclones during cancer progressi...